Chemical inhibitors of C20orf77 function through various biochemical mechanisms to inhibit the protein's activity. Staurosporine, a well-known protein kinase inhibitor, disrupts the phosphorylation events that are critical for the activity of many proteins, including C20orf77. By inhibiting these kinases, Staurosporine can prevent the phosphorylation that C20orf77 might require for its function. Similarly, Wortmannin and LY294002, both phosphoinositide 3-kinases (PI3K) inhibitors, disrupt signaling pathways that C20orf77 relies upon. By inhibiting PI3K, these chemicals can prevent the activation of downstream targets that may be essential for the function of C20orf77. Rapamycin, by inhibiting the mammalian target of rapamycin (mTOR), can also disrupt downstream signaling pathways associated with C20orf77, potentially inhibiting its function. This is similar to the action of U0126 and PD98059, which selectively inhibit MEK1/2 and MEK respectively, thereby preventing the activation of the ERK pathway, a pathway that C20orf77 may depend on for its activity.
Furthermore, SB203580 targets p38 MAP Kinase, which is involved in response to stress and cytokines. Inhibition of p38 MAPK by SB203580 can interrupt signaling cascades that C20orf77 is part of, leading to its inhibition. SP600125, a JNK inhibitor, can halt signaling processes that are essential for C20orf77's activity. Triciribine aims at AKT inhibition, which prevents the phosphorylation and activation of proteins that are in the same pathway as C20orf77, thus leading to its functional inhibition. Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can suppress the activity of kinases that regulate the activity of proteins such as C20orf77. Leflunomide inhibits dihydroorotate dehydrogenase, which can reduce the synthesis of proteins that are part of C20orf77's pathway, resulting in functional inhibition. Lastly, Bortezomib, as a proteasome inhibitor, causes the accumulation of misfolded proteins, disrupting cellular homeostasis and potentially inhibiting the function of C20orf77 through stress-induced pathways. Each chemical operates by disrupting specific pathways or cellular processes that are crucial for the proper functioning of C20orf77, thereby achieving inhibition.
関連項目
Items 1 to 10 of 12 total
画面:
製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
細胞周期の進行に関与するCDK4/6を阻害することで、C21orf77が細胞周期と関連している場合、C21orf77の活性を低下させる可能性がある。 | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
EGFRチロシンキナーゼを標的とし、C21orf77が関与する下流のシグナル伝達経路を阻害する可能性がある。 | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
BRAF V600Eを阻害し、メラノーマ細胞のC21orf77を含むシグナル伝達経路に影響を及ぼす可能性がある。 | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
AKTのリン酸化と活性化を阻害し、C21orf77を含むシグナル伝達経路を阻害する可能性がある。 | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
HMG-CoA還元酵素を阻害し、脂質ラフトやC21orf77が関与する関連シグナル伝達経路に影響を及ぼす可能性がある。 | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTORを阻害することで、C21orf77が関与するシグナル伝達経路を阻害し、そのタンパク質相互作用や局在に影響を与える可能性がある。 | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
E3ユビキチンリガーゼ複合体を介した特定のタンパク質の分解を調節する。この複合体の標的であれば、C21orf77も含まれる可能性がある。 | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCKキナーゼを阻害し、C21orf77が関与する細胞骨格組織やシグナル伝達経路に影響を及ぼす可能性がある。 | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEKを阻害し、C21orf77が関与するERK経路のシグナル伝達を変化させる可能性がある。 | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNKを阻害し、もしJNKシグナルがC21orf77の活性を調節するならば、C21orf77が関与するシグナル伝達経路に影響を与える可能性がある。 |